Evidence map›Paper›PMID 39299693›Full record

ReviewMagyar onkologia2024

[Robot-assisted radical prostatectomy].

Máté Németh, Jenő Zsolt Szepesváry, Péter Törzsök

Abstract readReview
In one paragraph

Review in Magyar onkologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Máté NémethUrológiai Osztály, Petz Aladár Egyetemi Oktató Kórház, Győr, Hungary. nemeth9mate@gmail.com.
Jenő Zsolt SzepesváryUrológiai Osztály, Petz Aladár Egyetemi Oktató Kórház, Győr, Hungary. nemeth9mate@gmail.com.
Péter TörzsökUrológiai Osztály, Petz Aladár Egyetemi Oktató Kórház, Győr, Hungary. nemeth9mate@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is one of the most commonly seen malignancies. Radical prostatectomy - open, laparoscopic or robot-assisted - is considered the first-line treatment for intermediate and high-risk prostate cancer, along with radiotherapy, if the expected survival is greater than 10 years. Radical prostatectomy is also considered in case of low-risk patients alongside active follow-up. Today, robot-assisted radical prostatectomy is the most common surgical treatment for localised prostate cancer. It is associated with shorter hospitalisation times and lower transfusion requirements compared to open surgery. Satisfactory long-term biochemical recurrence-free survival and tumour-specific survival can be achieved with robot-assisted radical prostatectomy in the treatment of low-, intermediate- and highrisk prostate cancer. It has the advantage of rapid postoperative continence recovery and high potency recovery rates. The cost of the minimal invasive approach is higher compared to open radical prostatectomy, and the benefits of faster postoperative recovery should be further investigated to quantify cost-effectiveness. The robot-assisted approach has enabled a number of new surgical techniques and further rapid advances in this field are expected.

Indexed as

ProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresCost-Benefit AnalysisDisease-Free SurvivalHumansLaparoscopyLength of StayMaleRoboticsTreatment Outcome

Identifiers

PMID39299693
PMCPMC11870689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.